The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
P25 is a major surface protein of Plasmodium ookinetes. Antibodies against P25 prevent the formation of oocysts in the mosquito and thereby block transmission of the parasite through an endemic population. Plasmodium vivax transmission-blocking vaccines based on Pv25 have undergone human trials and...
Main Authors: | Ramjanee, S, Robertson, J, Franke-Fayard, B, Sinha, R, Waters, A, Janse, C, Wu, Y, Blagborough, A, Saul, A, Sinden, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2007
|
Similar Items
-
Localisation and timing of expression of putative Plasmodium berghei rhoptry proteins in merozoites and sporozoites.
by: Tufet-Bayona, M, et al.
Published: (2009) -
Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro.
by: Blagborough, A, et al.
Published: (2009) -
The dynamics of interactions between Plasmodium and the mosquito: a study of the infectivity of Plasmodium berghei and Plasmodium gallinaceum, and their transmission by Anopheles stephensi, Anopheles gambiae and Aedes aegypti.
by: Alavi, Y, et al.
Published: (2003) -
Erratum: The dynamics of interactions between Plasmodium and the mosquito: A study of the infectivity of Plasmodium berghei and Plasmodium gallinaceum, and their transmission by Anopheles stephensi, Anopheles gambiae and Aedes aegypti (International Journal for Parasitology (2003) 33 (933-943))
by: Alavi, Y, et al.
Published: (2004) -
Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
by: Blagborough, A, et al.
Published: (2010)